When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
FATE - Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Fate Therapeutics Inc.
2024-01-26 09:13:32 ET
Summary
Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024.
The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article.
The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential.